Oral Diabetic Medications and the Geriatric Patient

Clinics in Geriatric Medicine

Volumn 24, Issue 3, 2008, Pages 541-549

  Silverberg, Alan B ^a   Ligaray, Kenneth Patrick L ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETOHEXAMIDE; ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; CHLORPROPAMIDE; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TOLAZAMIDE; TOLBUTAMIDE; VILDAGLIPTIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUTE HEART INFARCTION; ANEMIA; ANOREXIA; CARBOHYDRATE ABSORPTION; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TOLERABILITY; EDEMA; FLATULENCE; GERIATRIC PATIENT; GLUCONEOGENESIS; GLYCEMIC CONTROL; GLYCOGENOLYSIS; HEADACHE; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN RELEASE; KIDNEY FAILURE; LIVER FUNCTION TEST; LOW DRUG DOSE; METABOLIC CLEARANCE RATE; MONOTHERAPY; MORNING DOSAGE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PERIPHERAL FRACTURE; PROTEIN BINDING; REVIEW; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; AGED; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE;

EID: 47849100932     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cger.2008.03.012     Document Type: Review

References (48)

1. Qaseem A., Vijan S., Snow V., et al. Glycemic control and type 2 diabetes mellitus. The optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med 147 6 (2007) 417-422
2. American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care 31 3 (2008) 596-615
3. Rizvi A. Management of diabetes in older adults. Am J Med Sci 333 1 (2007) 35-47
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
5. The Diabetes Control and Complication Trial Research Group. The Effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
6. Diabetes Control and Complications Trial/Epidemioilogy of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Eng J Med 353 (2005) 2643-2653
7. Bolen S., Feldman L., Vassy J., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147 6 (2007) 386-399
8. Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management-2002. Update. Endocr Pract 8 (2002) 40-82
9. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 29 Suppl 1 (2006) S4-S42
10. California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 51 (2003) S265-S280
11. Canadian Diabetes Association Clnical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 27 Suppl 2 (2003) S1-S152
12. Drugs for diabetes. Treat Guidel Med Lett 1 1 (2002) 1-6
13. Ahren B., Simonsson E., Larsson H., et al. Inhibiton of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25 (2002) 869-875
14. Mazza A., and Morley J. Update on diabetes in the elderly and the application of current therapeutics. J Am Med Dir Assoc 8 (2007) 489-492
15. Nauck M., Meininger G., Sheng D., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 9 (2007) 194-205
16. Eng J., Kleinman W.A., Singh L., et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267 11 (1992) 7402-7405
17. Nelson P., Poon T., Guan X., et al. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther 9 4 (2007) 317-326
18. Drucker D.J., and Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 9548 (2006) 1696-1705
19. Mudaliar S., and Henry R.R. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 52 (2001) 239-257
20. Zinman B., Hoogwerf B.J., Durán García S., et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 146 7 (2007) 477-485
21. Lee A., Patrick P., Wishart J., et al. The effects of miglitol on glucagons-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 4 (2002) 329-335
22. Deleon M., Chandurkar V., Albert S., et al. Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects. Diabetes Res Clin Pract 56 (2002) 101-106
23. Chaisson J.L., Josse R.G., Gomis R., et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM rendomised trial. Lancet 359 (2002) 2072-2077
24. Bailey C.J., and Turner R.C. Metformin. N Engl J Med 334 (1996) 574-579
25. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13 Suppl 1 (2007) 1-68
26. Inzucchi S.E., Maggs D.G., Spollett G.R., et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338 (1998) 867-872
27. Hundal R.S., Krssak M., Dufour S., et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49 (2000) 2063-2069
28. Wilcock C., and Bailey C.J. Sites of metformin-stimulated glucose metabolism. Biochem Pharmacol 39 (1990) 1831-1834
29. Stumvoll M., Nurjhan N., Perriello G., et al. Metabolic effects of metformin on non-insulin-dependent diabetes mellitus. N Engl J Med 333 (1995) 550-554
30. Eriksson A., Attvall S., Bonnier M., et al. Short-term effects of metformin in type 2 diabetes. Diabetes Obes Metab 9 4 (2007) 483-489
31. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 30 (2007) S4-S41
32. Lee A., and Morley J.E. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 6 (1998) 47-53
33. Morley J.E., Kim M.J., Haren M.T., et al. Frailty and the aging male. [review]. Aging Male 8 3-4 (2005) 135-140
34. Chapman I.M. The anorexia of aging. Clin Geriatr Med 23 4 (2007) 735-756
35. Morley J.E. Weight loss in the nursing home. J Am Med Dir Assoc 8 (2007) 201-204
36. Kim M.J., Rolland Y., Cepeda O., et al. Diabetes mellitus in older men. Aging Male 9 (2006) 139-147
37. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131 (1999) 281-303
38. Metformin: drug information. Available at:. www.uptodate.com Accessed December 27, 2007
39. Albertini J.P., McMorn S.O., Chen H., et al. Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus. Atherosclerosis 195 1 (2007) e159-e166
40. Bell D.S. Triple oral therapy for type 2 diabetes. Diabetes Res Clin Pract 78 3 (2007) 313-315
41. Berhanu P., Perez A., and Yu S. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. Diabetes Obes Metab 9 4 (2007) 512-520
42. Hollander P., Yu D., and Chou H.S. Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes. Arch Intern Med 167 12 (2007) 1284-1290
43. Wilcox R., Bousser M.G., Betteridge D.J., et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROACTIVE (PROspective pioglitAzone Clinical Trial In macroVascular Events) 04. Stroke 38 3 (2007) 865-873
44. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 24 (2007) 2457-2471
45. Lipscombe L.L., Gomes T., Lévesque L.E., et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298 22 (2007) 2634-2643
46. Goldberg R.B. The new clinical trials with thiazolidinediones-DREAM, ADOPT, and CHICAGO: promises fulfilled?. Curr Opin Lipidol 18 4 (2007) 435-442
47. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 9541 (2006) 1096-1105
48. Deeks E.D., and Keam S.J. Rosiglitazone: a review of its use in type 2 diabetes mellitus. Drugs 67 18 (2007) 2747-2779